ATEC and Theradaptive Join Forces to Innovate Spinal Fusion Technologies for Enhanced Patient Outcomes

ATEC and Theradaptive's Transformative Partnership

In a significant move within the medical technology landscape, Alphatec Holdings, Inc. (NASDAQ: ATEC), renowned for its revolutionary spine surgery solutions, and Theradaptive, Inc., a pioneering company in engineered protein therapeutics, have established a strategic partnership. This collaboration is set to bring forward pioneering regenerative technologies, particularly in the realm of spinal fusion surgery.

Unveiling the Partnership

On January 12, 2026, the two companies announced their definitive agreement, which allows ATEC exclusive rights to market Theradaptive's OsteoAdapt®, a cutting-edge osteoinductive bone graft specifically designed for spinal fusion applications. This partnership is seen as a cornerstone in the engagement of regenerative medicine targeting the spinal industry, highlighting a mutual aspiration to enhance patient outcomes through innovative therapeutic approaches.

The agreement is structured to provide substantial long-term gains for both companies through upfront payments, milestone rewards, and ongoing royalties. The collaboration is strategically timed with Theradaptive also initiating a Series B investment round, aimed at accelerating the advancement and scaling of their proprietary protein-engineering technology across various therapeutic uses.

Technology Overview

At the heart of this collaboration is OsteoAdapt, which harnesses AMP2™ protein technology. This technology is currently being investigated in clinical trials focusing on spinal and dental procedures and is pending FDA Pre-Market Approval (PMA). The promising nature of this innovation is underscored by its receipt of three FDA Breakthrough Device Designations, which signal its potential to meet significant medical needs related to bone regeneration.

Pat Miles, ATEC's Chairman and CEO, expressed his enthusiasm about the partnership, stating, "This aligns with our continuous evolution of procedural ecosystems in spine surgery. Our company has pioneered a suite of solutions - from informatics to instrumentation, and now we have a biologic solution that has the potential to revolutionize fusion outcomes - OsteoAdapt is that imperative solution."

Synergistic Cooperation

The collaboration between ATEC and Theradaptive is structured to not just leverage current therapeutic applications, but also to integrate innovative solutions into ATEC's Organic Innovation Machine™. This initiative aims to set new benchmarks for clinical excellence in spine surgery by seamlessly integrating their spinal products and harnessing data to drive better surgical outcomes.

Luis Alvarez, Ph.D., CEO and Founder of Theradaptive, emphasized the importance of this partnership stating, "ATEC represents the ideal ally in our push towards providing advanced therapeutic options to patients. By merging our protein engineering capabilities with ATEC's extensive commercial outreach, we are well-positioned for a new chapter in regenerative medicine."

Market Landscape and Future Implications

The association between ATEC and Theradaptive operates within a thriving market. The U.S. spine surgery segment is valued at over $10 billion, with the biologics category alone accounting for a substantial $2 billion opportunity. OsteoAdapt aims to redefine market standards by presenting targeted solutions that could potentially phase out conventional allograft alternatives amidst rising demand for more effective biological agents in spinal interventions.

With ATEC's robust sales force, the anticipated sustained sales growth appears promising, projecting confidence in maximizing market outreach while delivering consistent financial return through ongoing royalties to Theradaptive.

Conclusion

The strategic partnership between Alphatec Holdings and Theradaptive signals a significant leap into a highly innovative era for regenerative medicine within the spine surgery sector. This collaboration not only combines their strengths—ATEC's established market reach and Theradaptive's advanced technological platform—but also reaffirms their shared commitment to improving patient care standards through pioneering solutions in spinal fusion therapy. The integration of OsteoAdapt into ATEC’s offerings could redefine therapeutic options for countless patients in need of more effective biomaterials for spinal regeneration. As they continue to navigate through clinical evaluations and scale their innovations, the future of spine surgery looks set to witness a transformative shift that enhances surgical outcomes and patient quality of life.